Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Diabetes Obes Metab. 2007;9:186-93.
Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome.
Endocr Rev. 2008;29:777-822.
Despres JP, Golay A, Sjostrom L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
N Engl J Med. 2005;353:2121-2134.
Freemark M. Pharmacotherapy of childhood obesity.
Diabetes Care. 2007;30:395-402.
Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity.
Ann Intern Med. 2005;142:532-546.
Orchar TJ, Temprosa M, Goldberg R, et al. The effect of diet and exercise or metformin on the metabolic syndrome: The diabetes prevention program randomized trial.
Annals of Internal Medicine. 2005;142:611-619.
Rosenstock J, Fitchet M. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.
Int J Clin Pract Suppl. 2008;159:15-23.
Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia.
Expert Opin Pharmacother. 2008; 9:1237-1248.
Steinberger J, Daniels SR, Eckel RH, et al. AHA Scienfic Statement: Progress and Challenges in Metabolic Syndrome in children and Adolescents.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.